Improved MRI technique for detecting spinal cord lesions in multiple sclerosis
3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME)
This study is testing a new MRI technique to see if it can find spinal cord lesions better than regular MRI scans in people with multiple sclerosis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 1 site (Bordeaux) |
| Trial ID | NCT05227092 on ClinicalTrials.gov |
What this trial studies
This study aims to compare a new 3D OPTIMIZED MPRAGE WMN MRI sequence with conventional imaging techniques for detecting spinal cord lesions in patients with multiple sclerosis. Participants will undergo MRI scans at both cervical and thoracic levels using various sequences, including the new optimized technique. The goal is to assess whether the new sequence provides better sensitivity and specificity in identifying lesions, which could enhance diagnosis and treatment planning for multiple sclerosis patients.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with clinically isolated syndrome (CIS) or relapsing-remitting multiple sclerosis (RRMS) who have experienced medullary symptoms for less than 6 months.
Not a fit: Patients with progressive multiple sclerosis or other neurological conditions, as well as those with contraindications to MRI, will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate detection of spinal cord lesions in multiple sclerosis, improving patient management and outcomes.
How similar studies have performed: While there have been advancements in MRI techniques for brain imaging in multiple sclerosis, the specific application of the 3D OPTIMIZED WMN MPRAGE sequence for spinal cord lesions is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients older than 18 years old * CIS or RRMS * Medullary symptomatology less than 6 months * With or without an objective lesion on a subsequent MRI scan * Signed the Informed Consent Exclusion Criteria: * Pregnant or potentially pregnant women * Breastfeeding woman * Contraindications to MRI * Other diagnosis (Neuro-myelitis spectrum disease or Progressive Multiple Sclerosis) * Surgical history on the spinal cord or lumbar spine * Patient under legal protection
Where this trial is running
Bordeaux
- CHU de Bordeaux — Bordeaux, France (Recruiting)
Study contacts
- Study coordinator: Vincent Dousset, MD, PhD
- Email: vincent.dousset@chu-bordeaux.fr
- Phone: +335 56 79 56 04
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.